Update from GOV.UK for: Vorasidenib approved to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
Update from GOV.UK for: News and communications Vorasidenib approved to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation Page summary: The Medicines and Healthcare products Regulatory…  | GOV.UK | | |
|
| Update from GOV.UK for: News and communications
Page summary:
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16th September 2025, approved the medicine vorasidenib (Voranigo). Change made:
First published. Time updated:
11:29am, 16 September 2025
Why am I getting this email?You asked GOV.UK to send you an email each time we add or update a page about: News and communications Unsubscribe Change your email preferences |
|
|
Kaffi's
Lorem Ipsum is simply dummy text of the printing and typesetting industry.
No comments:
Post a Comment